Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001600620-24-000108
Filing Date
2024-11-07
Accepted
2024-11-07 06:17:50
Documents
84
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q auph-20240930.htm   iXBRL 10-Q 1081537
2 EX-31.1 auph-2024q3exx311.htm EX-31.1 10871
3 EX-31.2 auph-2024q3exx312.htm EX-31.2 11013
4 EX-32.1 auph-2024q3exx321.htm EX-32.1 5343
5 EX-32.2 auph-2024q3exx322.htm EX-32.2 5351
  Complete submission text file 0001600620-24-000108.txt   6236438

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT auph-20240930.xsd EX-101.SCH 44159
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT auph-20240930_cal.xml EX-101.CAL 73728
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT auph-20240930_def.xml EX-101.DEF 182887
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT auph-20240930_lab.xml EX-101.LAB 516350
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT auph-20240930_pre.xml EX-101.PRE 363755
86 EXTRACTED XBRL INSTANCE DOCUMENT auph-20240930_htm.xml XML 893656
Mailing Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6
Business Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6 250-744-2487
Aurinia Pharmaceuticals Inc. (Filer) CIK: 0001600620 (see all company filings)

EIN.: 981231763 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36421 | Film No.: 241432960
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)